Cady, Roger, M.D.
12
0
0
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
25.0%
3 terminated/withdrawn out of 12 trials
75.0%
-11.5% vs industry average
75%
9 trials in Phase 3/4
133%
12 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency
Role: lead
Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction
Role: lead
Pilot Study Evaluating the Use of Nasal Carbon Dioxide for the Treatment of Cluster Headache
Role: lead
Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine
Role: lead
Pilot Study of VVD-101 for the Treatment of Delayed Alcohol-Induced Headaches
Role: lead
Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine
Role: lead
CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Menstrual Migraine Before and After Treximet
Role: lead
Treximet in the Treatment of Chronic Migraine
Role: lead
Treximet Trademark (TM) in the Prevention and Modification of Disease Progression in Migraine
Role: lead
Calcitonin Gene-related Peptide Levels in Chronic Migraine
Role: lead
Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction
Role: lead
"Completeness of Response" Following Treatment With Treximet™ for Migraine
Role: lead
All 12 trials loaded